Comparative Pharmacology
Head-to-head clinical analysis: DOPTELET SPRINKLE versus NPLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOPTELET SPRINKLE versus NPLATE.
DOPTELET SPRINKLE vs NPLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DOPTELET (avatrombopag) is a thrombopoietin receptor agonist that binds to and activates the thrombopoietin receptor on megakaryocytes and megakaryocyte precursor cells, leading to differentiation, proliferation, and increased platelet production.
Thrombopoietin receptor agonist that binds to and activates the thrombopoietin receptor (c-Mpl), stimulating megakaryocyte proliferation and differentiation, leading to increased platelet production.
10 mg (5 capsules) orally once daily for 5 consecutive days. Two to 4 hours before planned procedure, total dose should be taken 5 days prior to the procedure.
1 mcg/kg subcutaneously once weekly, based on actual body weight.
None Documented
None Documented
Terminal half-life approximately 31-35 hours; supports once-daily dosing
Terminal half-life is 1–2 days (median 1.4 days) after weekly SC dosing; supports weekly administration.
Fecal (approx. 59%), renal (approx. 31%) as unchanged drug and metabolites
Renal excretion is minimal (<5% as unchanged drug); metabolism is expected via proteolysis to small peptides and amino acids; no biliary/fecal data available.
Category C
Category C
Thrombopoietin Receptor Agonist
Thrombopoietin Receptor Agonist